These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36583088)

  • 1. Successful Use of Lanadelumab in an Older Patient With Type II Hereditary Angioedema.
    Hellu MT; Weiss MS; Smith D
    Fed Pract; 2022 Sep; 39(9):390-392. PubMed ID: 36583088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
    Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
    Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.
    Iaboni A; Kanani A; Lacuesta G; Song C; Kan M; Betschel SD
    Allergy Asthma Clin Immunol; 2021 Jul; 17(1):78. PubMed ID: 34301329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience.
    Abuzakouk M; Ghorab O; Al-Hameli H; Salvo F; Grandon D; Maurer M
    World Allergy Organ J; 2022 Jul; 15(7):100664. PubMed ID: 35891672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.
    Wong JCY; Chiang V; Lam DLY; Lee E; Lam K; Au EYL; Li PH
    J Allergy Clin Immunol Glob; 2023 Nov; 2(4):100166. PubMed ID: 38024849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
    Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
    JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.
    Petkova E; Yordanova V; Staevska M; Valerieva A
    Drug Healthc Patient Saf; 2022; 14():195-210. PubMed ID: 36578774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
    García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
    Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY
    Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Analysis in Patients With HAE Under Prophylaxis With Lanadelumab: A Real-life Experience.
    Hahn J; Trainotti S; Wigand MC; Schuler PJ; Hoffmann TK; Greve J
    J Drugs Dermatol; 2020 Oct; 19(10):978-983. PubMed ID: 33026762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
    Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
    Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor.
    Jones DH; Bansal P; Bernstein JA; Fatteh S; Harper J; Hsu FI; O'Connor M; Park N; Suez D
    World Allergy Organ J; 2022 Jan; 15(1):100621. PubMed ID: 35145604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
    Fain O; Du-Thanh A; Gobert D; Launay D; Inhaber N; Boudjemia K; Aubineau M; Sobel A; Boccon-Gibod I; Weiss L; Bouillet L
    Allergy Asthma Clin Immunol; 2022 Apr; 18(1):30. PubMed ID: 35365234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema.
    Gower RG; Wilber M
    Allergy Asthma Clin Immunol; 2021 Oct; 17(1):100. PubMed ID: 34627358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab.
    Shah CH; Princic N; Evans KA; Schultz BG
    J Med Econ; 2023; 26(1):871-877. PubMed ID: 37395381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.
    Craig T; Tachdjian R; Bernstein JA; Anderson J; Nurse C; Watt M; Yu M; Juethner S
    Ann Allergy Asthma Immunol; 2024 Aug; ():. PubMed ID: 39128590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.